EU agency recommends against Novartis heart failure drug

May 23, 2014 1:17 PM

14 0

EU agency recommends against Novartis heart failure drug

ZURICH (Reuters) - EU health regulators have recommended against approving Novartis's experimental heart failure drug for the second time this year due to insufficient evidence it improves symptoms, the Swiss drugmaker said in a statement on Friday.

The ruling by the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) follows a previous rebuffal given in January and dashes Novartis's hopes for approval of serelaxin in Europe this year.

Read more

To category page

Loading...